The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Modern Rheumatology

Volumn 27, Issue 1, 2017, Pages 42-49

  Kaneshiro, Shoichi ^a,b,c   Ebina, Kosuke ^b   Hirao, Makoto ^b   Tsuboi, Hideki ^c   Nishikawa, Masataka ^a   Nampei, Akihide ^d   Nagayama, Yoshio ^c   Takahi, Koichiro ^e   Noguchi, Takaaki ^b   Owaki, Hajime ^a   Hashimoto, Jun ^d   Yoshikawa, Hideki ^b  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Biologics; Inadequate response; Rheumatoid arthritis; Tacrolimus; Tocilizumab

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN; TACROLIMUS; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG RESPONSE; DRUG RETENTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG MONITORING; JAPAN; MIDDLE AGED; PATIENT ACUITY; PROCEDURES; PROSPECTIVE STUDY; REMISSION; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG MONITORING; FEMALE; HUMANS; JAPAN; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PATIENT ACUITY; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966930598     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2016.1181315     Document Type: Article

References (34)

1. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.
2. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study):a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update. Ann Rheum Dis. 2014;73(3):492–509.
4. Hirao M, Yamasaki N, Oze H, Ebina K, Nampei A, Kawato Y, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int. 2012;32(12):4041–5.
5. Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M, et al. IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab. 2014;32(4):378–92.
6. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis:the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.
7. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors:a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol. 2015;25(1):31–7.
8. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T., Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33(11):2153–61.
9. Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M, et al. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Mod Rheumatol. 2009;19(6):652–6.
10. Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol. 2010;37(3):512–20.
11. Yokota K, Akiyama Y, Asanuma Y, Miyoshi F, Sato K, Mimura T., Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis. Rheumatol Int. 2009;29(4):459–61.
12. Naniwa T, Watanabe M, Banno S, Maeda T., Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int. 2009;29(11):1287–91.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
14. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351–7.
15. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806.
16. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI):a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100–8.
17. Pincus T, Summey JA, Soraci Jr. SA, Wallston KA, Hummon NP., Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346–53.
18. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
19. van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34–40.
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.
21. Mori S., Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis. Mod Rheumatol. 2012;22(6):947–50.
22. Ishida K, Shiraki K, Yoshiyasu T., Evaluation of the safety and effectiveness of add-on tacrolimus in patients with rheumatoid arthritis who failed to show an adequate response to biological DMARDs:the interim results of a specific drug use-results survey of tacrolimus. Drugs R D. 2015;15(4):307–17.
23. Miwa Y, Hosaka M, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, et al. Depression is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing an inadequate response to biologic agents. Mod Rheumatol. 2013;23(5):920–4.
24. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130(7):1655–63.
25. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S., Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506:effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res. 2004;53(10):544–50.
26. Natsumeda M, Yamashita M, Takasugi K, Yamanaka R, Ezawa K, Ezawa K, et al. Study on the usefulness of adalimumab plus tacrolimus concomitant treatment given to rheumatoid arthritis patients intolerant to methotrexate (in Japanese). J New Rem Clin. 2014;63(1):95–104.
27. Choe JY, Park KY, Park SH, Lee SI, Kim SK., Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther. 2013;15(1):R26.
28. Zawawi MS, Dharmapatni AA, Cantley MD, McHugh KP, Haynes DR, Crotti TN., Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation. Biochem Biophys Res Commun. 2012;427(2):404–9.
29. Kawasaki Y, Moriyama M, Shibata K, Gomita Y., Effectiveness of methotrexate for the escape by salazosulfapyridine (in Japanese). Yakugaku Zasshi. 2005;125(7):579–82.
30. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004;9(12):1265–73.
31. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y., Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(6):1676–83.
32. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y., Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67(3):380–8.
33. Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D, et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int. 2015;35(10):1707–16.
34. Fujibayashi T, Takahashi N, Kida D, Kaneko A, Hirano Y, Fukaya N, et al. Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry. Mod Rheumatol. 2015;25(6):825–30.